In conclusion, our results show that the combination of PD-1 inhibitors plus lenvantinib or regorafenib in the treatment of advanced HCC has acceptable survival benefits and controllable side effects, however, their PFS and OS did not differ significantly. Here, PDCD1 is linked to hepatocellular carcinoma.